BP1.4979

Phase 2Small molecule

BBioprojet

BP1.4979 is one of 18 small molecule programs targeting Essential Tremor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential TremorRecruiting

Premature EjaculationRecruiting

Essential TremorPhase 2

Recruiting

Premature EjaculationPhase 2

Recruiting

Competition

Competitive Landscape

11 competitors in Premature Ejaculation

#DrugCompanyPhaseTrials

Xylocaine

MMEDRx USA, Inc.

Approved

1 2

Viagra

VViatris Specialty LLC

Approved

1 3

Botox

AbbVie

Phase 3

1 4

Standard Treatment

Boehringer Ingelheim

Phase 3

1 5

BP1.4979

BBioprojet

Phase 2

1 6

Botox

GGalderma R&D

Preclinical

1 7

Dapoxetine Hydrochloride

Johnson & Johnson

Preclinical

2 8

Bont-a

SSir Run Run Shaw Hospital

Preclinical

1 9

Serotonin Reuptake Inhibitor (SSRI)

MMedipol University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Essential Tremor

NCT07074002

Phase 2Recruiting

Premature Ejaculation

NCT07047404

Clinical

Trials by Indication[1]

Eating Disorder1 trial

Pilot Study on BP1.4979 Effect on Binge Eating Disorders

Completed·BBioprojet·Phase 2·NCT05118906·67 enrolled

Essential Tremor1 trial

Proof of Concept Study on BP1.4979 Effect on Essential Tremor

Recruiting·BBioprojet·Phase 2·NCT07074002·50 enrolled

Smoking Cessation1 trial

Efficacy and Safety of BP1.4979 in Smoking Cessation

Completed·BBioprojet·Phase 2·NCT01785147·219 enrolled

Premature Ejaculation1 trial

Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation

Recruiting·BBioprojet·Phase 2·NCT07047404·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BP1.4979. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BP1.4979 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BP1.4979. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bioprojet company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioprojet

BP1.4979

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Eating Disorder1 trial

Essential Tremor1 trial

Smoking Cessation1 trial

Premature Ejaculation1 trial

References

Drug Info

Quick Facts

Related News